Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

1 DuBois SG, Macy, ME, Henderson TO. High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes. American Society of Clinical Oncology Educational Book [Internet]. 2022 Jul;(42):768–80. Available from: http://dx.doi.org/10.1200/edbk_349783
2 St. Jude Children’s Hospital. Neuroblastoma. Available from: https://www.stjude.org/disease/neuroblastoma.html
3 News Medical Life Sciences. European scientists target high-risk childhood cancer with liquid biopsy. Available from: https://www.news-medical.net/news/20240129/European-scientists-target-high-risk-childhood-cancer-with-liquid-biopsy.aspx#:~:text=Neuroblastoma%20mainly%20affects%20toddlers%20and,patients%20are%20high%2Drisk%20cases
4 Furman WL, McCarville B, Shulkin BL, Davidoff A, Krasin M, Hsu CW, et al. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. Journal of Clinical Oncology [Internet]. 2022 Feb 1;40(4):335–44. Available from: http://dx.doi.org/10.1200/jco.21.01375 Read More

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma